{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:18Z","timestamp":1793155698175,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of the study was to investigate the prognostic value of previously established ceramide\u2013phospholipid risk score, CERT2, and its response to lipid-lowering treatments in patients with symptomatic or suspected coronary heart disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and results:<\/jats:title>\n                    <jats:p>\n                      Selected ceramides and phospholipids were analyzed with a quantitative liquid chromatography\u2013mass spectrometry-based method from plasma or serum samples obtained from the Angiography and Genes study (ANGES, N = 966), and placebo-controlled trials investigating atorvastatin and simvastatin (N = 44) and proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor RG7652 (N = 78). In the ANGES, the adjusted hazard ratios (95% confidence interval) per SD for the CERT2 risk score were 1.71 (1.42\u20132.08) for cardiovascular disease death, 1.36 (1.13\u20131.64) for myocardial infarction, 1.40 (1.20\u20131.63) for heart failure, 1.23 (1.08\u20131.40) for atrial fibrillation, 1.09 (0.89\u20131.33) for stroke, and 1.52 (1.06\u20132.18) for venous thromboembolism. The median decrease of the CERT2 risk score was 2 points by statin treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.001) and 3 points by PCSK9 inhibition (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) on the 0\u201312 scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The CERT2 risk score is a significant predictor of cardiovascular outcomes in all-comer patients with symptomatic or suspected coronary heart disease. Treatment with lipid-lowering medication significantly lowers the CERT2 risk score.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fjc.0000000000001817","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:00:15Z","timestamp":1782468015000},"page":"161-165","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ceramide\u2013Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments"],"prefix":"10.1097","volume":"88","author":[{"given":"Mika","family":"Hilvo","sequence":"first","affiliation":[{"name":"VTT Technical Research Centre of Finland Ltd, Espoo, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-652X","authenticated-orcid":false,"given":"Angelika","family":"Witoslawska","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"L\u00e4\u00e4peri","sequence":"additional","affiliation":[{"name":"Zora Biosciences Oy, Espoo, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Jylh\u00e4","sequence":"additional","affiliation":[{"name":"Zora Biosciences Oy, Espoo, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo-Pekka","family":"Lyytik\u00e4inen","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"},{"name":"Faculty of Medicine and Health Technology, Tampere University, and Department of Clinical Chemistry, Fimlab Laboratories. Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"P\u00e4iv\u00e4","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, Tampere University, and Department of Clinical Chemistry, Fimlab Laboratories. Tampere, Finland;"},{"name":"Division One, Department of Internal Medicine, Tampere University Hospital, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Laurikka","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"},{"name":"Department of Cardio-Thoracic Surgery, Heart Center, Tampere University Hospital; Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[{"name":"Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology, Pneumology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; and"},{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka J.","family":"Karhunen","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"},{"name":"Faculty of Medicine and Health Technology, Tampere University, and Department of Clinical Chemistry, Fimlab Laboratories. Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terho","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"},{"name":"Faculty of Medicine and Health Technology, Tampere University, and Department of Clinical Chemistry, Fimlab Laboratories. Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reijo","family":"Laaksonen","sequence":"additional","affiliation":[{"name":"Finnish Cardiovascular Research Center - Tampere, Tampere University, Tampere, Finland;"},{"name":"Zora Biosciences Oy, Espoo, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-Year risk of recurrent vascular events and residual risk in a secondary prevention PopulationClinical perspective","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"R2-20260807","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R3-20260807","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"R4-20260807","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/eurheartj\/ehz387","article-title":"Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients","volume":"41","author":"Hilvo","year":"2020","journal-title":"Eur Heart J"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1210\/jc.2013-2559","article-title":"Molecular lipids identify cardiovascular risk and are efficiently lowered by Simvastatin and PCSK9 deficiency","volume":"99","author":"Tarasov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1530\/JOE-16-0381","article-title":"Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle","volume":"233","author":"Zabielski","year":"2017","journal-title":"The J Endocrinol"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diabet.2017.04.003","article-title":"Fenofibrate decreases plasma ceramide in type 2 diabetes patients: a novel marker of CVD?","volume":"44","author":"Croyal","year":"2018","journal-title":"Diabetes Metab"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/00365510802172145","article-title":"Diagnostic performance of plasma high sensitive C\u2010reactive protein in detecting three\u2010vessel coronary artery disease: modification by apolipoprotein E genotype","volume":"68","author":"Mennander","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR Study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1007\/s00216-016-9425-z","article-title":"Development and validation of a high-throughput LC-MS\/MS assay for routine measurement of molecular ceramides","volume":"408","author":"Kauhanen","year":"2016","journal-title":"Anal Bioanal Chem"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up","volume":"359","year":"2002","journal-title":"Lancet (London, England)"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"The New Engl J Med"},{"key":"R17-20260807","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"e005708","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","article-title":"Plasma ceramides and sphingomyelins in relation to heart failure risk","volume":"12","author":"Lemaitre","year":"2019","journal-title":"Circ Heart Fail"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"e013050","DOI":"10.1161\/JAHA.119.013050","article-title":"Association of circulating ceramides with cardiac structure and function in the community: the Framingham heart Study","volume":"8","author":"Nwabuo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ehf2.12133","article-title":"Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise","volume":"4","author":"Mueller-Hennessen","year":"2017","journal-title":"ESC Heart Fail"},{"key":"R21-20260807","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jpba.2018.03.027","article-title":"LC\u2013MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure","volume":"154","author":"Marcinkiewicz-Siemion","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"e012853","DOI":"10.1161\/JAHA.119.012853","article-title":"Plasma ceramides and sphingomyelins in relation to atrial fibrillation risk: the cardiovascular health Study","volume":"9","author":"Jensen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R23-20260807","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/ATVBAHA.112.300210","article-title":"Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus Formation","volume":"34","author":"M\u00fcnzer","year":"2014","journal-title":"Arteriosclerosis, Thromb Vasc Biol"},{"key":"R24-20260807","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.13553","article-title":"Omega-3 fatty acids predict recurrent venous thromboembolism or total mortality in elderly patients with acute venous thromboembolism","volume":"15","author":"Reiner","year":"2017","journal-title":"J Thromb Haemost JTH"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FJC.0000000000001817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:08Z","timestamp":1787747588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FJC.0000000000001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000001817","relation":{},"ISSN":["1533-4023"],"issn-type":[{"value":"1533-4023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2025-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}